These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35831408)

  • 1. Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation.
    Massoud R; Klyuchnikov E; Gagelmann N; Zabelina T; Wolschke C; Ayuk F; Fritzsche-Friedland U; Zander A; Kröger N
    Bone Marrow Transplant; 2022 Oct; 57(10):1548-1555. PubMed ID: 35831408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
    Massoud R; Gagelmann N; Fritzsche-Friedland U; Zeck G; Heidenreich S; Wolschke C; Ayuk F; Christopeit M; Kröger N
    Haematologica; 2022 Apr; 107(4):857-867. PubMed ID: 33832208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
    Gooptu M; Kim HT; Chen YB; Rybka W; Artz A; Boyer M; Johnston L; McGuirk J; Shea TC; Jagasia M; Shaughnessy PJ; Reynolds CG; Fields M; Alyea EP; Ho VT; Glavin F; Dipersio JF; Westervelt P; Ritz J; Soiffer RJ
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2216-2223. PubMed ID: 30006305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower incidence of grade II-IV acute Graft-versus-Host-Disease in pediatric patients recovering with high Vδ2+ T cells after allogeneic stem cell transplantation with unmanipulated bone marrow grafts: a prospective single-center cohort study.
    Müller T; Alasfar L; Preuß F; Zimmermann L; Streitz M; Hundsdörfer P; Eggert A; Schulte J; von Stackelberg A; Oevermann L
    Front Immunol; 2024; 15():1433785. PubMed ID: 39136029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.
    Servais S; Menten-Dedoyart C; Beguin Y; Seidel L; Gothot A; Daulne C; Willems E; Delens L; Humblet-Baron S; Hannon M; Baron F
    PLoS One; 2015; 10(6):e0130026. PubMed ID: 26098781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
    Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
    Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy.
    Leserer S; Graf T; Franke M; Bogdanov R; Arrieta-Bolaños E; Buttkereit U; Leimkühler N; Fleischhauer K; Reinhardt HC; Beelen DW; Turki AT
    Front Immunol; 2023; 14():1082727. PubMed ID: 37020562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies.
    Turki AT; Klisanin V; Bayraktar E; Kordelas L; Trenschel R; Ottinger H; Steckel NK; Tsachakis-Mück N; Leserer S; Ditschkowski M; Liebregts T; Koldehoff M; Fleischhauer K; Beelen DW
    Am J Transplant; 2020 Mar; 20(3):677-688. PubMed ID: 31597002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Lymphocyte Subsets of Grafts on the Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation.
    Jiang P; Yu F; Xu X; Cai Y; Yang J; Tong Y; Huang C; Qiu H; Zhou K; Zhang Y; Niu J; Shen C; Xia X; Wei Y; Shao J; Gao L; Song X; Wan L
    Cell Transplant; 2023; 32():9636897231157054. PubMed ID: 36905323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
    Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
    Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
    Front Immunol; 2019; 10():1997. PubMed ID: 31507601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation.
    Nikoloudis A; Buxhofer-Ausch V; Aichinger C; Binder M; Hasengruber P; Kaynak E; Wipplinger D; Milanov R; Strassl I; Stiefel O; Machherndl-Spandl S; Petzer A; Weltermann A; Clausen J
    Cells; 2023 Jul; 12(14):. PubMed ID: 37508496
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors.
    Jiang P; Cai Y; Zhou X; Yang J; Tong Y; Huang C; Qiu H; Zhou K; Xu X; Zhang Y; Niu J; Shen C; Xia X; Wei Y; Song X; Wan L
    Clin Transplant; 2023 Jan; 37(1):e14844. PubMed ID: 36318732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation.
    Ito A; Kitano S; Tajima K; Kim Y; Tanaka T; Inamoto Y; Kim SW; Yamamoto N; Fukuda T; Okamoto S
    Int J Hematol; 2020 Jan; 111(1):120-130. PubMed ID: 31641956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.
    Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
    Soiffer RJ; Kim HT; McGuirk J; Horwitz ME; Johnston L; Patnaik MM; Rybka W; Artz A; Porter DL; Shea TC; Boyer MW; Maziarz RT; Shaughnessy PJ; Gergis U; Safah H; Reshef R; DiPersio JF; Stiff PJ; Vusirikala M; Szer J; Holter J; Levine JD; Martin PJ; Pidala JA; Lewis ID; Ho VT; Alyea EP; Ritz J; Glavin F; Westervelt P; Jagasia MH; Chen YB
    J Clin Oncol; 2017 Dec; 35(36):4003-4011. PubMed ID: 29040031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.
    Admiraal R; Nierkens S; Bierings MB; Bredius RGM; van Vliet I; Jiang Y; Lopez-Yurda M; Versluijs AB; Zwaan CM; Lindemans CA; Boelens JJ
    Lancet Haematol; 2022 Feb; 9(2):e111-e120. PubMed ID: 35114150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.